CR11749A - Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina - Google Patents

Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina

Info

Publication number
CR11749A
CR11749A CR11749A CR11749A CR11749A CR 11749 A CR11749 A CR 11749A CR 11749 A CR11749 A CR 11749A CR 11749 A CR11749 A CR 11749A CR 11749 A CR11749 A CR 11749A
Authority
CR
Costa Rica
Prior art keywords
relaxin
treatment
disnea
acute cardiac
cardiac insufficiency
Prior art date
Application number
CR11749A
Other languages
English (en)
Inventor
Unemori Elaine
L Teichman Sam
Cotter Gad
R Stewart Dennis
Jo Whitehouse Martha
Original Assignee
Corthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera Inc filed Critical Corthera Inc
Publication of CR11749A publication Critical patent/CR11749A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La descripción pertenece a los métodos para reducir la descompensación a través de la intervención aguda, incluyendo en los sujetos afligidos con insuficiencia cardiaca aguda descompensada. Particularmente, la descripción proporciona métodos para el tratamiento de la descompensación cardiaca aguda, mediante la administración de una cantidad farmacéuticamente efectiva de relaxina
CR11749A 2008-05-16 2010-10-22 Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina CR11749A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US19054508P 2008-08-28 2008-08-28
US20124008P 2008-12-08 2008-12-08
US16433309P 2009-03-27 2009-03-27

Publications (1)

Publication Number Publication Date
CR11749A true CR11749A (es) 2011-02-11

Family

ID=40834101

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11749A CR11749A (es) 2008-05-16 2010-10-22 Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina

Country Status (30)

Country Link
US (7) US8415301B2 (es)
EP (2) EP2288373B1 (es)
JP (4) JP5651586B2 (es)
CN (3) CN103212063B (es)
AR (1) AR071810A1 (es)
AU (1) AU2009246114B2 (es)
BR (1) BRPI0913011A2 (es)
CA (1) CA2724540C (es)
CR (1) CR11749A (es)
CY (1) CY1116925T1 (es)
DK (1) DK2288373T3 (es)
EA (2) EA201500552A1 (es)
ES (1) ES2546287T3 (es)
GB (2) GB2459983B (es)
HK (5) HK1139051A1 (es)
HR (1) HRP20150845T1 (es)
HU (1) HUE025483T2 (es)
IL (3) IL208992A (es)
MA (1) MA32389B1 (es)
MX (1) MX2010012450A (es)
MY (2) MY159803A (es)
NZ (3) NZ701038A (es)
PL (1) PL2288373T3 (es)
PT (1) PT2288373E (es)
SG (2) SG191587A1 (es)
SI (1) SI2288373T1 (es)
TW (1) TWI386202B (es)
UA (1) UA99953C2 (es)
WO (1) WO2009140659A2 (es)
ZA (1) ZA201007449B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2459983B (en) * 2008-05-16 2010-04-28 Corthera Inc Methods of treating dyspnea associated with acute heart failure
CA2724535A1 (en) * 2008-05-16 2009-11-19 Elaine Unemori Use of relaxin to treat chronic heart failure
BR112012022654A2 (pt) * 2010-03-10 2016-11-01 Univ Florida modulação de aquaporinas com relaxina
EP2601532B1 (en) * 2010-08-06 2016-01-27 Mycartis N.V. Perlecan as a biomarker for renal dysfunction
MA34521B1 (fr) 2010-08-17 2013-09-02 Ambrx Inc Polypeptides de relaxine modifiés et leurs utilisations
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
JP2014522641A (ja) * 2011-07-01 2014-09-08 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング リラキシン融合ポリペプチドおよびその使用
WO2013059879A1 (en) * 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
EP2814513B1 (en) * 2012-02-14 2017-12-20 The Regents of The University of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
ES2929283T3 (es) 2012-05-04 2022-11-28 Us Health Moduladores del receptor de relaxina 1
TR201807636T4 (tr) 2012-10-26 2018-06-21 Chiesi Farm Spa Kalp yetmezliğinde kan basıncının kontrol edilmesi ve dispnenin azaltılması için yöntemler.
AU2014248164B2 (en) 2013-04-05 2019-05-23 Scpharmaceuticals, Inc. Pharmaceutical formulations for subcutaneous administration of furosemide
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN106031247A (zh) * 2014-02-03 2016-10-12 诺华股份有限公司 用于输液装置的过滤器
EP2946788A1 (en) * 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
KR20170018829A (ko) * 2014-06-13 2017-02-20 노파르티스 아게 Gdf-15를 감소시키기 위한 세렐락신의 용도
EP3387019B1 (en) 2015-12-09 2021-10-20 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
WO2017139164A1 (en) 2016-02-12 2017-08-17 Cardiac Pacemakers, Inc. Systems and methods for patient monitoring
TW201837051A (zh) 2017-02-08 2018-10-16 美商必治妥美雅史谷比公司 包含藥物動力學增強劑之經修飾之鬆弛素(relaxin)多肽及其用途
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
CN113271923A (zh) 2019-01-04 2021-08-17 Sq创新股份公司 呋塞米的药物组合物及其用途
CA3128033A1 (en) 2019-01-31 2020-08-06 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
WO2024047130A1 (en) 2022-08-31 2024-03-07 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Immunosuppressive medicament and method of treatment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5478807A (en) * 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
DE69432704T2 (de) 1993-06-21 2004-02-26 Genentech, Inc., South San Francisco Verfahren zur Herstellung von humanen Relaxin
WO1995003822A2 (en) 1993-07-27 1995-02-09 Mario Bigazzi Use of relaxin as therapeutic or preventing agent
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
WO1997006814A1 (en) 1995-08-15 1997-02-27 Connective Therapeutics, Inc. Method of promoting angiogenesis
AU2001236886A1 (en) 2000-02-09 2001-08-20 Connetics Corporation Use of relaxin to treat diseases related to vasoconstriction
DE10155843A1 (de) * 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
KR100749857B1 (ko) * 2004-03-30 2007-08-16 연세대학교 산학협력단 릴랙신 유전자를 포함하는 유전자 전달 시스템 및 릴랙신을이용한 약제학적 조성물
US20060264367A1 (en) * 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
US20080077025A1 (en) * 2005-07-11 2008-03-27 Leticia Delgado-Herrera Methods for determining how to treat congestive heart failure
AU2008273813B2 (en) 2007-07-12 2013-06-13 Compugen Ltd. Bioactive peptides and method of using same
CA2724535A1 (en) 2008-05-16 2009-11-19 Elaine Unemori Use of relaxin to treat chronic heart failure
GB2459983B (en) * 2008-05-16 2010-04-28 Corthera Inc Methods of treating dyspnea associated with acute heart failure

Also Published As

Publication number Publication date
JP2015013870A (ja) 2015-01-22
UA99953C2 (uk) 2012-10-25
TW200948353A (en) 2009-12-01
US9066916B2 (en) 2015-06-30
AR071810A1 (es) 2010-07-14
JP5875646B2 (ja) 2016-03-02
ES2546287T3 (es) 2015-09-22
GB0918132D0 (en) 2009-12-02
US8053411B2 (en) 2011-11-08
US20130210730A1 (en) 2013-08-15
CN103212063B (zh) 2015-07-22
US9205132B2 (en) 2015-12-08
HK1151229A1 (en) 2012-01-27
SG10201609580YA (en) 2016-12-29
EP2829280A1 (en) 2015-01-28
CN103212063A (zh) 2013-07-24
US8415301B2 (en) 2013-04-09
AU2009246114A1 (en) 2009-11-19
HK1187550A1 (zh) 2014-04-11
CN102036679A (zh) 2011-04-27
SI2288373T1 (sl) 2015-12-31
GB2459983A (en) 2009-11-18
GB2462221B (en) 2010-09-01
IL247351A0 (en) 2016-09-29
WO2009140659A3 (en) 2010-07-22
IL208992A (en) 2013-09-30
HUE025483T2 (en) 2016-02-29
GB0908432D0 (en) 2009-06-24
HK1202054A1 (en) 2015-09-18
SG191587A1 (en) 2013-07-31
MY159803A (en) 2017-02-15
HRP20150845T1 (hr) 2015-11-06
EA201500552A1 (ru) 2016-07-29
MX2010012450A (es) 2011-03-21
DK2288373T3 (en) 2015-09-28
JP2011520918A (ja) 2011-07-21
GB2462221A (en) 2010-02-03
NZ701038A (en) 2016-01-29
US20170151311A1 (en) 2017-06-01
TWI386202B (zh) 2013-02-21
EP2288373A2 (en) 2011-03-02
CN106177914A (zh) 2016-12-07
MA32389B1 (fr) 2011-06-01
NZ589009A (en) 2012-05-25
US20120040902A1 (en) 2012-02-16
US9579363B2 (en) 2017-02-28
CA2724540C (en) 2014-07-08
PL2288373T3 (pl) 2015-11-30
HK1140693A1 (en) 2010-10-22
HK1139051A1 (en) 2010-09-10
WO2009140659A2 (en) 2009-11-19
JP5651586B2 (ja) 2015-01-14
CY1116925T1 (el) 2017-04-05
JP2016053040A (ja) 2016-04-14
ZA201007449B (en) 2011-06-29
EA022948B1 (ru) 2016-03-31
MY158327A (en) 2016-09-30
BRPI0913011A2 (pt) 2019-09-03
GB2459983B (en) 2010-04-28
EA201001771A1 (ru) 2011-06-30
US20120040903A1 (en) 2012-02-16
US20130116181A1 (en) 2013-05-09
US20100048475A1 (en) 2010-02-25
JP5638044B2 (ja) 2014-12-10
US20150320834A1 (en) 2015-11-12
IL228244A (en) 2016-10-31
EP2288373B1 (en) 2015-06-24
JP2013040174A (ja) 2013-02-28
NZ598709A (en) 2013-09-27
CA2724540A1 (en) 2009-11-19
AU2009246114B2 (en) 2013-01-31
IL208992A0 (en) 2011-01-31
US8372809B2 (en) 2013-02-12
PT2288373E (pt) 2015-10-19

Similar Documents

Publication Publication Date Title
CR11749A (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
MX336145B (es) Metodo para el tratamiento de insuficiencia cardiaca cronica.
CL2012002037A1 (es) Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca
ECSP10010106A (es) Trans-clomifeno para el síndrome metabólico
CL2011001529A1 (es) Uso de un modulador o agonista de los receptores s1p derivado de 2-amino-propan-1,3-diol o 2-amino-propanol para tratar una enfermedad cronica larga en un sujeto, de manera de conseguir una disminucion diaria en la frecuencia cardiaca de 2 latidos/minutos o menos; y kit que lo comprende.
PA8794401A1 (es) Acidos 6-fenilnicotinicos sustituidos y su uso
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
CY1123900T1 (el) Χρηση toy fk506 για τη θεραπεια της πνευμονικης αρτηριακης υπερτασης
UY33369A (es) Heterociclilbencil-pirazoles sustituidos y su uso
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
NI201000173A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre.
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
CL2009001018A1 (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia, teniendo los pacientes un incremento del nivel de creatinina debido a la utilizacion de dronedarona.
UY32507A (es) Una dosis de ave5026 para el tratamiento de trombormbolismo venoso en pacientes con deterioro renal severo
CO6300936A2 (es) Procedimiento para revertir la remodelacion cardiaca electrofisiologica de un animal con cardiopatia usando beta-adrenoceptores
ES2578729T3 (es) Agente terapéutico para enfermedades relacionadas con el hígado
AU2016219717A1 (en) Treating dyspnea associated with acute heart failure with relaxin
CU20100225A7 (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
PH12016500711A1 (en) Method of treating dyspnea associated with acute heart failure
TN2010000504A1 (en) Treating dyspnea associated with acute heart failure with relaxin
AU2013201629B2 (en) Treating dyspnea associated with acute heart failure with relaxin
MD3987B1 (en) Use of Diosmine for the treatment of advancing hepatic cirrhosis associated with cardiac insufficiency
UA69733U (ru) Способ диагностики диастолической дисфункции левого желудочка у больных с неосложненной гипертонической болезнью
UA53527U (ru) Способ комплексного лечения хронической сердечной недостаточности у больных пожилого возраста с ишемической болезнью сердца